Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

At Nearly $200, Are CSL Shares Overrated?

CSL Limited (ASX: CSL) shares are a favourite blue-chip for many ASX investors but, with the share price near $200, are the shares overrated?

About CSL

CSL is Australia’s largest (and many might say ‘best’) health biotechnology company, specialising in biopharmaceuticals.

Founded in the late 1900s as the Commonwealth Serum Laboratories, ‘CSL’ was sold by the Australian Government to shareholders via the ASX in 1994 at only $2.30 a pop. It used the money to double its size through an international acquisition.

CSL is now a global leader in blood plasma vaccines (think: the flu, snake bite anti-venoms, etc.), providing relief for potentially life-threatening medical conditions.

Shares Struggle To Stay Above $200

Over the last 12 months, CSL shares have risen by 18.5%. In that time, they’ve been as high as $230 and as low as $170, so it hasn’t been a smooth ride.

More recent price movements paint a different picture of low growth, but still a lot of volatility. In a six-month period, the share price has risen only 4.7%, but again with a high of $202 and a low of $175.

Over the last month, the share price seems to have found a comfortable spot, growing just 0.5% and with much lower volatility.

The clear pattern over the last year has been that the share price averages around $200. I think this is about the fair value of CSL, although maybe it could stretch slightly higher – say $205?

Even if CSL shares are worth $205 though, that’s only a 2.5% increase from the current share price.

The current dividend yield on offer is just 1.23% — hardly groundbreaking.

So What Now?

I think CSL is a great business. In fact, I think it might actually be one of the highest-quality businesses Australia has to offer. However, I also think CSL shares have found their fair value around $200 and I don’t see much growth in the share price in the near future.

For another price, I wouldn’t hesitate to buy CSL shares. But with a low dividend yield and a share price very close to fair value, I think there are better ASX shares to buy right now.

A good place to start looking is the companies in the free report below.

3 Proven, Dividend-Paying Companies

[ls_content_block id=”14945″ para=”paragraphs”]

Disclaimer: At the time of writing, Max does not own shares in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content